icon-folder.gif   Conference Reports for NATAP  
  50th ICAAC
Boston, MA
September 12-15, 2010
Back grey_arrow_rt.gif
GSK2248761, an NNRTI with Activity Against Common NNRTI Resistance Mutants, Did Not Select for NNRTI Resistance Mutations in Two 7-Day Monotherapy Studies
  Reported by Jules Levin
ICAAC Sept 14 2010 Boston

The 30mg dose appears suboptimal & the other diseases appear to provide similar declines in viral load. Dr St Clair said 100 & 200mg were selected to be studied.